PTC Therapeutics Inc (PTCT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $65.37 (-3.87%), Market cap $6.03B, 52-week low–high $43.30 ~ $86.25.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for th
Financial statements, price targets, institutional (13F) holdings and related news for PTC Therapeutics Inc are updated in real time on BlackAll Trade.
PTC Therapeutics Inc trades at $65.37 (-3.87%). Real-time quotes and charts are available on BlackAll Trade.
PTC Therapeutics Inc has a market cap of about $6.03B.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States an